Indivior Pharmaceuticals (INDV) stock: insider trades, news & valuation
Health Care · Strong buyingShare price and insider trades
Indivior Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 7 insiders bought $310K and 2 sold $2.8M of INDV stock on the open market, including a cluster buy that began Jan 5, 2026; P/E 12.8 vs. a sector median of 24.7.
Get emailed when insiders cluster-buy stocks like INDV
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
INDV insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $108K | 2 | $765K | 1 |
| Q2 2026 | — | 0 | $2.1M | 2 |
| Q1 2026 | $204K | 8 | — | 0 |
Valuation, profit and volume
Pick score 57/100Summary
Over the past 12 months, 7 Indivior Pharmaceuticals, Inc. insiders reported open-market purchases totaling $310K, while 2 insiders reported sales totaling $2.8M. The most recent cluster buy began on Jan 5, 2026, when 5 insiders bought a combined $172K. 3 of 3 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
INDV stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 27SEC | Woodrow D AndersonChief Accounting Officer | Buy | 1,50027,638 held (+6%) | $35.69 | $54K | +0.4% | — |
| Aug 5SEC | Woodrow D AndersonChief Accounting Officer | Buy | 1,50026,138 held (+6%) | $36.28 | $54K | -1.2% | — |
| Jul 13SEC | Christian HeidbrederChief Scientific Officer | Sell Plan | 18,586209,337 held (−8%) | $41.14 | $765K | -12.9% | — |
| Jun 12SEC | Christian HeidbrederChief Scientific Officer | Sell Plan | 18,586227,923 held (−8%) | $38.06 | $707K | -5.9% | — |
| Jun 10SEC | Ryan PreblickCFO | Sell Plan | 36,000284,751 held (−11%) | $37.70 | $1.4M | -5.0% | — |
| Mar 13SEC | Barbara RyanDirector | Buy | 85,724 held (+0%) | $31.09 | $249 | +15.2% | — |
| Mar 11SEC | Stuart A KingsleyDirector | Buy | 9405,582 held (+20%) | $31.87 | $30K | +12.4% | — |
| Mar 11SEC | Barbara RyanDirector | Buy | 315,716 held (+1%) | $32.56 | $1K | +10.0% | — |
| Jan 7SEC | David E. WheadonDirector | Buy | 1,77114,395 held (+14%) | $35.39 | $63K | +1.2% | — |
| Jan 7SEC | Daniel A NinivaggiDirector | Buy | 77516,923 held (+5%) | $35.39 | $27K | +1.2% | — |
| Jan 7SEC | Barbara RyanDirector | Buy | 7751,963 held (+65%) | $35.39 | $27K | +1.2% | — |
| Jan 7SEC | Mark StejbachDirector | Buy | 77516,847 held (+5%) | $35.39 | $27K | +1.2% | — |
| Jan 7SEC | Keith HumphreysDirector | Buy | 7755,802 held (+15%) | $35.39 | $27K | +1.2% | — |
Insiders at Indivior Pharmaceuticals, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Christian HeidbrederChief Scientific Officer | — | $1.5M | Jul 13, 2026 | — |
| Ryan PreblickCFO | — | $1.4M | Jun 10, 2026 | — |
| Woodrow D AndersonChief Accounting Officer | $108K | — | Aug 27, 2026 | — |
| David E. WheadonDirector | $63K | — | Jan 7, 2026 | — |
| Stuart A KingsleyDirector | $30K | — | Mar 11, 2026 | — |
| Barbara RyanDirector | $29K | — | Mar 13, 2026 | — |
| Daniel A NinivaggiDirector | $27K | — | Jan 7, 2026 | — |
| Mark StejbachDirector | $27K | — | Jan 7, 2026 | — |
| Keith HumphreysDirector | $27K | — | Jan 7, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
INDV stock: common questions
Are Indivior Pharmaceuticals, Inc. insiders buying INDV stock?
In the past 12 months, 7 insiders reported open-market purchases of INDV worth $310K. The latest was Chief Accounting Officer Woodrow D Anderson bought $54K of INDV at $35.69.
Are Indivior Pharmaceuticals, Inc. insiders selling INDV stock?
2 insiders reported sales worth $2.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is INDV's P/E ratio?
INDV trades at about 12.8 times trailing earnings, compared with a median of 24.7 for the Health Care sector.
What is INDV's 52-week range?
Over the past year INDV has traded between $23.78 and $41.83. It last closed at $35.83 on Oct 9, 2026.